Bob Van De Water

List of Publications by Year in Descending Order

67 papers	3,382 citations	30 h-index	58 g-index
71 ext. papers	3,943 ext. citations	6.5 avg, IF	4.84 L-index

#	Paper	IF	Citations
67	A quantitative AOP of mitochondrial toxicity based on data from three cell lines.. *Toxicology in Vitro* , **2022**, 105345	3.6	2
66	High-content high-throughput imaging reveals distinct connections between mitochondrial morphology and functionality for OXPHOS complex I, III, and V inhibitors.. *Cell Biology and Toxicology*, **2022**, 1	7.4	0
65	The human hepatocyte TXG-MAPr: gene co-expression network modules to support mechanism-based risk assessment. *Archives of Toxicology*, **2021**, 95, 3745-3775	5.8	1
64	Mapping the cellular response to electron transport chain inhibitors reveals selective signaling networks triggered by mitochondrial perturbation. *Archives of Toxicology*, **2021**, 1	5.8	2
63	A read-across case study on chronic toxicity of branched carboxylic acids (1): Integration of mechanistic evidence from new approach methodologies (NAMs) to explore a common mode of action. *Toxicology in Vitro*, **2021**, 79, 105269	3.6	2
62	Squaramide-Based Supramolecular Materials Drive HepG2 Spheroid Differentiation. *Advanced Healthcare Materials*, **2021**, 10, e2001903	10.1	3
61	Comparing in vitro human liver models to in vivo human liver using RNA-Seq. *Archives of Toxicology*, **2021**, 95, 573-589	5.8	12
60	In Vitro Three-Dimensional Liver Models for Nanomaterial DNA Damage Assessment. *Small*, **2021**, 17, e2006055	11	8
59	Differential reprogramming of breast cancer subtypes in 3D cultures and implications for sensitivity to targeted therapy. *Scientific Reports*, **2021**, 11, 7259	4.9	5
58	Dynamic Modeling of Mitochondrial Membrane Potential Upon Exposure to Mitochondrial Inhibitors. *Frontiers in Pharmacology*, **2021**, 12, 679407	5.6	2
57	Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. *Archives of Toxicology*, **2021**, 95, 591-615	5.8	9
56	Multiparametric assessment of mitochondrial respiratory inhibition in HepG2 and RPTEC/TERT1 cells using a panel of mitochondrial targeting agrochemicals. *Archives of Toxicology*, **2020**, 94, 2707-2729	5.8	13
55	Identification of mitochondrial toxicants by combined in silico and in vitro studies A structure-based view on the adverse outcome pathway. *Computational Toxicology*, **2020**, 14, 100123	3.1	7
54	Statement on advancing the assessment of chemical mixtures and their risks for human health and the environment. *Environment International*, **2020**, 134, 105267	12.9	81
53	Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. *Nature Reviews Drug Discovery*, **2020**, 19, 131-148	64.1	82
52	In vitro 3D phenotypic drug screen identifies celastrol as an effective in vivo inhibitor of polycystic kidney disease. *Journal of Molecular Cell Biology*, **2020**, 12, 644-653	6.3	6
51	High-throughput confocal imaging of differentiated 3D liver-like spheroid cellular stress response reporters for identification of drug-induced liver injury liability. *Archives of Toxicology*, **2019**, 93, 2895-2911	5.8	25

50	Advancing human health risk assessment. *EFSA Journal*, **2019**, 17, e170712	2.3	19
49	Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations. *Archives of Toxicology*, **2019**, 93, 1609-1637	5.8	53
48	Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury. *Archives of Toxicology*, **2019**, 93, 385-399	5.8	18
47	Dynamic imaging of adaptive stress response pathway activation for prediction of drug induced liver injury. *Archives of Toxicology*, **2018**, 92, 1797-1814	5.8	36
46	Systems Microscopy Approaches in Unraveling and Predicting Drug-Induced Liver Injury (DILI). *Methods in Pharmacology and Toxicology*, **2018**, 611-625	1.1	1
45	Current EU research activities on combined exposure to multiple chemicals. *Environment International*, **2018**, 120, 544-562	12.9	119
44	Case Studies in Cellular Stress: Defining Adversity/Adaptation Tipping Points. *Applied in Vitro Toxicology*, **2017**, 3, 199-210	1.3	7
43	Adverse outcome pathways: opportunities, limitations and open questions. *Archives of Toxicology*, **2017**, 91, 3477-3505	5.8	174
42	Unraveling cellular pathways contributing to drug-induced liver injury by dynamical modeling. *Expert Opinion on Drug Metabolism and Toxicology*, **2017**, 13, 5-17	5.5	11
41	Drug-Induced Liver Injury and TNF-Signaling: FromIn VivoUnderstanding toIn VitroTesting Approaches. *Applied in Vitro Toxicology*, **2016**, 2, 197-206	1.3	1
40	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. *BMC Medicine*, **2015**, 13, 156	11.4	37
39	Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of In Vitro Models. *Applied in Vitro Toxicology*, **2015**, 1, 175-186	1.3	5
38	Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant. *Journal of Clinical Investigation*, **2015**, 125, 1648-64	15.9	81
37	A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies. *Archives of Toxicology*, **2014**, 88, 1083-95	5.8	211
36	Toxicogenomics directory of chemically exposed human hepatocytes. *Archives of Toxicology*, **2014**, 88, 2261-87	5.8	74
35	An Overview of Toxicogenomics Approaches to Mechanistically Understand and Predict Kidney Toxicity **2014**, 213-234		1
34	TNF-mediated NF-B survival signaling impairment by cisplatin enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells. *Biochemical Pharmacology*, **2013**, 85, 274-86	6	56
33	The nuclear factor B family member RelB facilitates apoptosis of renal epithelial cells caused by cisplatin/tumor necrosis factor synergy by suppressing an epithelial to mesenchymal transition-like phenotypic switch. *Molecular Pharmacology*, **2013**, 84, 128-38	4.3	19

32	Silencing of doublecortin-like (DCL) results in decreased mitochondrial activity and delayed neuroblastoma tumor growth. *PLoS ONE*, **2013**, 8, e75752	3.7	11
31	cAMP signalling protects proximal tubular epithelial cells from cisplatin-induced apoptosis via activation of Epac. *British Journal of Pharmacology*, **2012**, 165, 1137-50	8.6	25
30	Two-photon intravital multicolour imaging to study metastatic behaviour of cancer cells in vivo. *Methods in Molecular Biology*, **2011**, 769, 331-49	1.4	9
29	Focal adhesion kinase signaling mediates acute renal injury induced by ischemia/reperfusion. *American Journal of Pathology*, **2011**, 179, 2766-78	5.8	10
28	Two-photon intravital multicolor imaging combined with inducible gene expression to distinguish metastatic behavior of breast cancer cells in vivo. *Molecular Imaging and Biology*, **2011**, 13, 67-77	3.8	13
27	Diclofenac inhibits tumor necrosis factor-□nduced nuclear factor-B activation causing synergistic hepatocyte apoptosis. *Hepatology*, **2011**, 53, 2027-41	11.2	76
26	Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 6340-5	11.5	151
25	Systems microscopy approaches to understand cancer cell migration and metastasis. *Cellular and Molecular Life Sciences*, **2010**, 67, 3219-40	10.3	28
24	Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways. *Human Molecular Genetics*, **2009**, 18, 2532-42	5.6	116
23	Complete focal adhesion kinase deficiency in the mammary gland causes ductal dilation and aberrant branching morphogenesis through defects in Rho kinase-dependent cell contractility. *FASEB Journal*, **2009**, 23, 3482-93	0.9	24
22	An improved model to study tumor cell autonomous metastasis programs using MTLn3 cells and the Rag2(-/-) gammac (-/-) mouse. *Clinical and Experimental Metastasis*, **2009**, 26, 673-84	4.7	24
21	Macrophage p53 controls macrophage death in atherosclerotic lesions of apolipoprotein E deficient mice. *Atherosclerosis*, **2009**, 207, 399-404	3.1	24
20	Annexin A2 phosphorylation mediates cell scattering and branching morphogenesis via cofilin Activation. *Molecular and Cellular Biology*, **2008**, 28, 1029-40	4.8	86
19	Focal adhesion kinase: a potential target in cancer therapy. *Biochemical Pharmacology*, **2007**, 73, 597-609	6	248
18	A portrait of cisplatin-induced transcriptional changes in mouse embryonic stem cells reveals a dominant p53-like response. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2007**, 617, 58-70	3.3	15
17	An improved method to study NK-independent mechanisms of MTLn3 breast cancer lung metastasis. *Clinical and Experimental Metastasis*, **2007**, 24, 379-87	4.7	5
16	Proteomic analysis of alternative protein tyrosine phosphorylation in 1,2-dichlorovinyl-cysteine-induced cytotoxicity in primary cultured rat renal proximal tubular cells. *Journal of Pharmacology and Experimental Therapeutics*, **2007**, 322, 89-100	4.7	10
15	Focal adhesion kinase and protein kinase B cooperate to suppress doxorubicin-induced apoptosis of breast tumor cells. *Molecular Pharmacology*, **2006**, 70, 1330-9	4.3	34

14	Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoE-deficient mice. *FASEB Journal*, **2006**, 20, 953-5	0.9	25
13	Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation. *Cancer Research*, **2005**, 65, 4698-706	10.1	118
12	Heat shock protein 27 is the major differentially phosphorylated protein involved in renal epithelial cellular stress response and controls focal adhesion organization and apoptosis. *Journal of Biological Chemistry*, **2005**, 280, 29885-98	5.4	74
11	Differential regulation of doxorubicin-induced mitochondrial dysfunction and apoptosis by Bcl-2 in mammary adenocarcinoma (MTLn3) cells. *Journal of Biological Chemistry*, **2002**, 277, 35869-79	5.4	75
10	Differential regulation of phosphatidylserine externalization and DNA fragmentation by caspases in anticancer drug-induced apoptosis of rat mammary adenocarcinoma MTLn3 cells. *Biochemical Pharmacology*, **2001**, 62, 1087-97	6	33
9	Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. *Circulation Research*, **2001**, 88, 780-6	15.7	124
8	Suppression of chemically induced apoptosis but not necrosis of renal proximal tubular epithelial (LLC-PK1) cells by focal adhesion kinase (FAK). Role of FAK in maintaining focal adhesion organization after acute renal cell injury. *Journal of Biological Chemistry*, **2001**, 276, 36183-93	5.4	47
7	Linking gene expression to mechanisms of toxicity. *Toxicology Letters*, **2000**, 112-113, 479-86	4.4	18
6	Dephosphorylation of focal adhesion kinase (FAK) and loss of focal contacts precede caspase-mediated cleavage of FAK during apoptosis in renal epithelial cells. *Journal of Biological Chemistry*, **1999**, 274, 13328-37	5.4	106
5	The roles of caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of renal epithelial cells. *Oncogene*, **1999**, 18, 6505-12	9.2	65
4	Endoplasmic reticulum stress proteins block oxidant-induced Ca2+ increases and cell death. *Journal of Biological Chemistry*, **1998**, 273, 12858-62	5.4	155
3	Endoplasmic reticulum chaperones GRP78 and calreticulin prevent oxidative stress, Ca2+ disturbances, and cell death in renal epithelial cells. *Journal of Biological Chemistry*, **1997**, 272, 21751-9	5.4	311
2	Alkylation-induced oxidative cell injury of renal proximal tubular cells: involvement of glutathione redox-cycle inhibition. *Archives of Biochemistry and Biophysics*, **1996**, 327, 71-80	4.1	31
1	The relationship between intracellular Ca2+ and the mitochondrial membrane potential in isolated proximal tubular cells from rat kidney exposed to the nephrotoxin 1,2-dichlorovinyl-cysteine. *Biochemical Pharmacology*, **1993**, 45, 2259-67	6	30